Katalin Andrea Wilkinson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7083320/publications.pdf

Version: 2024-02-01

141 papers

11,539 citations

53 h-index 30087 103 g-index

152 all docs

152 docs citations

times ranked

152

10668 citing authors

#	Article	IF	CITATIONS
1	An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature, 2010, 466, 973-977.	27.8	1,632
2	Predictive value of interferon-Î ³ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2012, 12, 45-55.	9.1	441
3	IFN- \hat{I}^3 - and TNF-Independent Vitamin D-Inducible Human Suppression of Mycobacteria: The Role of Cathelicidin LL-37. Journal of Immunology, 2007, 178, 7190-7198.	0.8	383
4	A Single Dose of Vitamin D Enhances Immunity to Mycobacteria. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 208-213.	5.6	370
5	Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet, The, 2001, 357, 2017-2021.	13.7	365
6	Neutrophil-mediated innate immune resistance to mycobacteria. Journal of Clinical Investigation, 2007, 117, 1988-1994.	8.2	352
7	Enumeration of T Cells Specific for RD1â€Encoded Antigens Suggests a High Prevalence of Latent <i>Mycobacterium tuberculosis</i> li>Infection in Healthy Urban Indians. Journal of Infectious Diseases, 2001, 183, 469-477.	4.0	335
8	Direct Ex Vivo Analysis of Antigen-Specific IFN-Î ³ -Secreting CD4 T Cells in <i>Mycobacterium tuberculosis</i> Infected Individuals: Associations with Clinical Disease State and Effect of Treatment. Journal of Immunology, 2001, 167, 5217-5225.	0.8	329
9	Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. Aids, 2002, 16, 2285-2293.	2.2	276
10	Transcriptional Blood Signatures Distinguish Pulmonary Tuberculosis, Pulmonary Sarcoidosis, Pneumonias and Lung Cancers. PLoS ONE, 2013, 8, e70630.	2.5	254
11	Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet, The, 2014, 384, 682-690.	13.7	229
12	Acquired predisposition to mycobacterial disease due to autoantibodies to IFN- \hat{l}^3 . Journal of Clinical Investigation, 2005, 115, 2480-2488.	8.2	206
13	Effect of HIV-1 Infection on T-Cell–based and Skin Test Detection of Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 514-520.	5.6	195
14	Detectable Changes in The Blood Transcriptome Are Present after Two Weeks of Antituberculosis Therapy. PLoS ONE, 2012, 7, e46191.	2.5	190
15	Comparison of T-SPOT. <i>TB</i> Assay and Tuberculin Skin Test for the Evaluation of Young Children at High Risk for Tuberculosis in a Community Setting. Pediatrics, 2009, 123, 38-43.	2.1	186
16	Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19013-19017.	7.1	174
17	Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography. Nature Medicine, 2016, 22, 1090-1093.	30.7	166
18	Frequency, Severity, and Prediction of Tuberculous Meningitis Immune Reconstitution Inflammatory Syndrome. Clinical Infectious Diseases, 2013, 56, 450-460.	5.8	162

#	Article	IF	CITATIONS
19	Ex Vivo Characterization of Early Secretory Antigenic Target 6-Specific T Cells at Sites of Active Disease in Pleural Tuberculosis. Clinical Infectious Diseases, 2005, 40, 184-187.	5.8	155
20	1α,25â€dihydroxyvitamin D ₃ inhibits matrix metalloproteinases induced by <i>Mycobacterium tuberculosis</i> infection. Immunology, 2009, 127, 539-548.	4.4	141
21	Type 1 Helper T Cells and FoxP3-positive T Cells in HIV–Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 1083-1089.	5.6	140
22	Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. European Respiratory Journal, 2011, 37, 1248-1259.	6.7	130
23	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1305-1320.	13.2	123
24	Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2015, 3, 190-200.	10.7	122
25	Relationship of SARS-CoV-2–specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection. Journal of Clinical Investigation, 2021, 131, .	8.2	113
26	Mycobacterial Antigen Driven Activation of CD14++CD16â° Monocytes Is a Predictor of Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. PLoS Pathogens, 2014, 10, e1004433.	4.7	111
27	Association between Gc genotype and susceptibility to TB is dependent on vitamin D status. European Respiratory Journal, 2010, 35, 1106-1112.	6.7	110
28	Effect of Treatment of Latent Tuberculosis Infection on the T Cell Response to <i>Mycobacterium tuberculosis </i> Antigens. Journal of Infectious Diseases, 2006, 193, 354-359.	4.0	109
29	Programmed death ligand 1 is overâ \in expressed by neutrophils in the blood of patients with active tuberculosis. European Journal of Immunology, 2011, 41, 1941-1947.	2.9	104
30	A deletion defining a common Asian lineage of <i>Mycobacterium tuberculosis </i> associates with immune subversion. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15594-15598.	7.1	100
31	Complement pathway gene activation and rising circulating immune complexes characterize early disease in HIV-associated tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E964-E973.	7.1	96
32	High frequencies of circulating IFN-Î ³ -secreting CD8 cytotoxic T cells specific for a novel MHC class I-restrictedMycobacterium tuberculosis epitope inM. tuberculosis-infected subjects without disease. European Journal of Immunology, 2000, 30, 2713-2721.	2.9	94
33	Novel Relationship between Tuberculosis Immune Reconstitution Inflammatory Syndrome and Antitubercular Drug Resistance. Clinical Infectious Diseases, 2009, 48, 667-676.	5.8	93
34	The Immune Response to <i>Mycobacterium tuberculosis</i> ion HIV-1-Coinfected Persons. Annual Review of Immunology, 2018, 36, 603-638.	21.8	85
35	Interaction of (i) Mycobacterium tuberculosis (i)-Induced Transforming Growth Factor \hat{I}^21 and Interleukin-10. Infection and Immunity, 1999, 67, 5730-5735.	2.2	83
36	High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening. Thorax, 2011, 66, 669-673.	5.6	81

#	Article	IF	CITATIONS
37	HIV–tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling. Nature Communications, 2015, 6, 8451.	12.8	81
38	Human T- and B-Cell Reactivity to the 16 kDa alpha-Crystallin Protein of Mycobacterium tuberculosis. Scandinavian Journal of Immunology, 1998, 48, 403-409.	2.7	79
39	Clinical, Immunological, and Epidemiological Importance of Antituberculosis T Cell Responses in HIV-Infected Africans. Clinical Infectious Diseases, 2007, 44, 1639-1646.	5.8	79
40	The stress-responsive chaperone \hat{l}_{\pm} -crystallin 2 is required for pathogenesis of Mycobacterium tuberculosis. Molecular Microbiology, 2004, 55, 1127-1137.	2.5	77
41	Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. ELife, 2020, 9, .	6.0	76
42	Corticosteroid-modulated Immune Activation in the Tuberculosis Immune Reconstitution Inflammatory Syndrome. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 369-377.	5.6	75
43	Modern Lineages of Mycobacterium tuberculosis Exhibit Lineage-Specific Patterns of Growth and Cytokine Induction in Human Monocyte-Derived Macrophages. PLoS ONE, 2012, 7, e43170.	2.5	72
44	Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosis. Tuberculosis, 2011, 91, 587-593.	1.9	71
45	Corticosteroid Therapy, Vitamin D Status, and Inflammatory Cytokine Profile in the HIV-Tuberculosis Immune Reconstitution Inflammatory Syndrome. Clinical Infectious Diseases, 2012, 55, 1004-1011.	5.8	70
46	Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. Nature Medicine, 2021, 27, 1362-1366.	30.7	70
47	Peptideâ€Specific T Cell Response to <i>Mycobacterium tuberculosis:</i> Clinical Spectrum, Compartmentalization, and Effect of Chemotherapy. Journal of Infectious Diseases, 1998, 178, 760-768.	4.0	69
48	Neutrophil-Associated Central Nervous System Inflammation in Tuberculous Meningitis Immune Reconstitution Inflammatory Syndrome. Clinical Infectious Diseases, 2014, 59, 1638-1647.	5.8	68
49	Biomarkers of Cerebral Injury and Inflammation in Pediatric Tuberculous Meningitis. Clinical Infectious Diseases, 2017, 65, 1298-1307.	5.8	67
50	The bacillary and macrophage response to hypoxia in tuberculosis and the consequences for T cell antigen recognition. Microbes and Infection, 2017, 19, 177-192.	1.9	66
51	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1321-1337.	13.2	66
52	Infection Biology of a Novel $\hat{l}\pm$ -Crystallin of <i>Mycobacterium tuberculosis</i> :Acr2. Journal of Immunology, 2005, 174, 4237-4243.	0.8	64
53	Polyfunctional T cells in human tuberculosis. European Journal of Immunology, 2010, 40, 2139-2142.	2.9	63
54	Dissection of Regenerating T-Cell Responses against Tuberculosis in HIV-infected Adults Sensitized by Mycobacterium tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 674-683.	5.6	60

#	Article	IF	CITATIONS
55	Activation Profile of <i>Mycobacterium tuberculosis</i> –Specific CD4 ⁺ T Cells Reflects Disease Activity Irrespective of HIV Status. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1307-1310.	5.6	60
56	Inflammasome activation underlies central nervous system deterioration in HIV-associated tuberculosis. Journal of Infectious Diseases, 2017, 215, jiw561.	4.0	57
57	Gamma Interferon-Based Immunodiagnosis of Tuberculosis: Comparison between Whole-Blood and Enzyme-Linked Immunospot Methods. Journal of Clinical Microbiology, 2004, 42, 829-831.	3.9	55
58	An increase in expression of a Mycobacterium tuberculosis mycolyl transferase gene (fbpB) occurs early after infection of human monocytes. Molecular Microbiology, 2001, 39, 813-821.	2.5	54
59	Tuberculous meningitis in children is characterized by compartmentalized immune responses and neural excitotoxicity. Nature Communications, 2019, 10, 3767.	12.8	52
60	Conserved Immune Recognition Hierarchy of Mycobacterial PE/PPE Proteins during Infection in Natural Hosts. PLoS ONE, 2012, 7, e40890.	2.5	50
61	Matrix Degradation in Human Immunodeficiency Virus Type 1–Associated Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study. Clinical Infectious Diseases, 2017, 65, 121-132.	5.8	50
62	Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer Cell, 2022, 40, 114-116.	16.8	50
63	Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers. Vaccine, 1999, 17, 1814-1819.	3.8	48
64	Matrix metalloproteinases and tissue damage in HIV â€tuberculosis immune reconstitution inflammatory syndrome. European Journal of Immunology, 2014, 44, 127-136.	2.9	48
65	Clinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: A prospective cohort study. PLoS Medicine, 2019, 16, e1002840.	8.4	48
66	Bioinformatic and Empirical Analysis of Novel Hypoxia-Inducible Targets of the Human Antituberculosis T Cell Response. Journal of Immunology, 2012, 189, 5867-5876.	0.8	44
67	TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development. Frontiers in Immunology, 2017, 8, 1203.	4.8	44
68	Differential Effect of Viable Versus Necrotic Neutrophils on Mycobacterium tuberculosis Growth and Cytokine Induction in Whole Blood. Frontiers in Immunology, 2018, 9, 903.	4.8	40
69	HIVâ€I infection alters CD4 ⁺ memory Tâ€cell phenotype at the site of disease in extrapulmonary tuberculosis. European Journal of Immunology, 2012, 42, 147-157.	2.9	38
70	Effect of Deletion or Overexpression of the 19-Kilodalton Lipoprotein Rv3763 on the Innate Response to Mycobacterium tuberculosis. Infection and Immunity, 2005, 73, 6831-6837.	2.2	37
71	A Glucuronoxylomannan-Associated Immune Signature, Characterized by Monocyte Deactivation and an Increased Interleukin 10 Level, Is a Predictor of Death in Cryptococcal Meningitis. Journal of Infectious Diseases, 2016, 213, 1725-1734.	4.0	37
72	Mycobacterium tuberculosis Induction of Heme Oxygenase-1 Expression Is Dependent on Oxidative Stress and Reflects Treatment Outcomes. Frontiers in Immunology, 2017, 8, 542.	4.8	37

#	Article	IF	CITATIONS
73	Detection of tuberculosis in HIV-infected children using an enzyme-linked immunospot assay. Aids, 2009, 23, 961-969.	2.2	35
74	Hypoxia Induces an Immunodominant Target of Tuberculosis Specific T Cells Absent from Common BCG Vaccines. PLoS Pathogens, 2010, 6, e1001237.	4.7	35
75	Association between Tuberculin Skin Test Reactivity, the Memory CD4 Cell Subset, and Circulating FoxP3-Expressing Cells in HIV-Infected Persons. Journal of Infectious Diseases, 2009, 199, 702-710.	4.0	34
76	Risk Factors Associated with Indeterminate Gamma Interferon Responses in the Assessment of Latent Tuberculosis Infection in a High-Incidence Environment. Vaccine Journal, 2012, 19, 1243-1247.	3.1	34
77	Matrix Metalloproteinases in Pulmonary and Central Nervous System Tuberculosisâ€"A Review. International Journal of Molecular Sciences, 2019, 20, 1350.	4.1	34
78	Reduction of Chemokine Secretion in Response to Mycobacteria in Infliximab-Treated Patients. Vaccine Journal, 2008, 15, 506-512.	3.1	32
79	Transmission of Mycobacterium tuberculosis Undetected by Tuberculin Skin Testing. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1038-1042.	5.6	31
80	Cytotoxic Mediators in Paradoxical HIV–Tuberculosis Immune Reconstitution Inflammatory Syndrome. Journal of Immunology, 2015, 194, 1748-1754.	0.8	31
81	Prevalence, Hemodynamics, and Cytokine Profile of Effusive-Constrictive Pericarditis in Patients with Tuberculous Pericardial Effusion. PLoS ONE, 2013, 8, e77532.	2.5	31
82	Enhanced diagnosis of HIV-1-associated tuberculosis by relating T-SPOT.TB and CD4 counts. European Respiratory Journal, 2010, 36, 594-600.	6.7	29
83	Altered Ratio of IFN-γ/IL-10 in Patients with Drug Resistant Mycobacterium tuberculosis and HIV-Tuberculosis Immune Reconstitution Inflammatory Syndrome. PLoS ONE, 2012, 7, e46481.	2.5	29
84	38 000 MW antigenâ€specific major histocompatibility complex class I restricted interferonâ€Ĵ³â€secreting CD8+T cells in healthy contacts of tuberculosis. Immunology, 1998, 95, 585-590.	4.4	28
85	Smoking, BCG and Employment and the Risk of Tuberculosis Infection in HIV-Infected Persons in South Africa. PLoS ONE, 2012, 7, e47072.	2.5	28
86	Role of the Interleukin 10 Family of Cytokines in Patients With Immune Reconstitution Inflammatory Syndrome Associated With HIV Infection and Tuberculosis. Journal of Infectious Diseases, 2013, 207, 1148-1156.	4.0	28
87	Reversion and conversion of Mycobacterium tuberculosis IFN-γ ELISpot results during anti-tuberculous treatment in HIV-infected children. BMC Infectious Diseases, 2010, 10, 138.	2.9	27
88	Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms. European Respiratory Journal, 2012, 39, 163-171.	6.7	26
89	Synthesis and in Vitro T-Cell Immunogenicity of Conjugates with Dual Specificity:Â Attachment of Epitope Peptides of 16 and 38 kDa Proteins fromMycobacterium tuberculosisto Branched Polypeptide. Bioconjugate Chemistry, 1998, 9, 539-547.	3.6	25
90	Population tailored modification of tuberculosis specific interferon-gamma release assay. Journal of Infection, 2016, 72, 179-188.	3.3	23

#	Article	IF	Citations
91	The CSF Immune Response in HIV-1–Associated Cryptococcal Meningitis: Macrophage Activation, Correlates of Disease Severity, and Effect of Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 299-307.	2.1	23
92	Neutrophil Activation and Enhanced Release of Granule Products in HIV-TB Immune Reconstitution Inflammatory Syndrome. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 221-229.	2.1	23
93	Immune Responses to the Enduring Hypoxic Response Antigen Rv0188 Are Preferentially Detected in Mycobacterium bovis Infected Cattle with Low Pathology. PLoS ONE, 2011, 6, e21371.	2.5	23
94	Effect of Antiretroviral Therapy on HIV-mediated Impairment of the Neutrophil Antimycobacterial Response. Annals of the American Thoracic Society, 2015, 12, 1627-37.	3.2	22
95	Evaluation of Host Serum Protein Biomarkers of Tuberculosis in sub-Saharan Africa. Frontiers in Immunology, 2021, 12, 639174.	4.8	21
96	Enhancement of the T cell response to a mycobacterial peptide by conjugation to synthetic branched polypeptide. European Journal of Immunology, 1999, 29, 2788-2796.	2.9	20
97	Genetic determination of the effect of post-translational modification on the innate immune response to the 19 kDa lipoprotein of Mycobacterium tuberculosis. BMC Microbiology, 2009, 9, 93.	3.3	20
98	Latency-Associated Peptide of Transforming Growth Factor Î ² Enhances Mycobacteriocidal Immunity in the Lung during Mycobacterium bovis BCG Infection in C57BL/6 Mice. Infection and Immunity, 2000, 68, 6505-6508.	2.2	19
99	Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: a case-control study. BMC Infectious Diseases, 2014, 14, 71.	2.9	19
100	Hemostatic changes associate with mortality in hospitalized patients with HIV-associated tuberculosis: a prospective cohort study. Journal of Infectious Diseases, 2017, 215, jiw532.	4.0	19
101	Mortality in Severe Human Immunodeficiency Virus-Tuberculosis Associates With Innate Immune Activation and Dysfunction of Monocytes. Clinical Infectious Diseases, 2017, 65, 73-82.	5. 8	19
102	Interleukin-17 mediated differences in the pathogenesis of HIV-1-associated tuberculous and cryptococcal meningitis. Aids, 2015, 30, 1.	2.2	19
103	Enhancement of the human T cell response to culture filtrate fractions of Mycobacterium tuberculosis by microspheres. Journal of Immunological Methods, 2000, 235, 1-9.	1.4	17
104	Raised Venous Lactate and Markers of Intestinal Translocation Are Associated With Mortality Among In-Patients With HIV-Associated TB in Rural South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 406-413.	2.1	17
105	Recognition of Mycobacterial Antigens Delivered by Genetically Detoxified Bordetella pertussis Adenylate Cyclase by T Cells from Cattle with Bovine Tuberculosis. Infection and Immunity, 2004, 72, 6255-6261.	2.2	16
106	Scientific letter: Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) and Galectin-3 levels in tuberculous pericardial effusion: implications for pathogenesis and prevention of pericardial constriction. Heart, 2012, 98, 1326.1-1328.	2.9	16
107	Baseline sebum ILâ€1α is higher than expected in afroâ€ŧextured hair: a risk factor for hair loss?*. Journal of Cosmetic Dermatology, 2012, 11, 9-16.	1.6	16
108	A novel assay of antimycobacterial activity and phagocytosis by human neutrophils. Tuberculosis, 2013, 93, 167-178.	1.9	16

#	Article	IF	Citations
109	Invariant Natural Killer T-cell Dynamics in Human Immunodeficiency Virus–associated Tuberculosis. Clinical Infectious Diseases, 2020, 70, 1865-1874.	5.8	15
110	Efficient Ex Vivo Stimulation of Mycobacterium tuberculosis-Specific T Cells by Genetically Detoxified Bordetella pertussis Adenylate Cyclase Antigen Toxoids. Infection and Immunity, 2005, 73, 2991-2998.	2.2	14
111	Enhanced Ex Vivo Stimulation of Mycobacterium tuberculosis -Specific T Cells in Human Immunodeficiency Virus-Infected Persons via Antigen Delivery by the Bordetella pertussis Adenylate Cyclase Vector. Vaccine Journal, 2007, 14, 847-854.	3.1	14
112	A Compartmentalized Profibrotic Immune Response Characterizes Pericardial Tuberculosis, Irrespective of HIV-1 Infection. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1518-1521.	5.6	14
113	Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2-specific T-cells. European Respiratory Journal, 2022, 59, 2100285.	6.7	14
114	A Recent HIV Diagnosis Is Associated with Non-Completion of Isoniazid Preventive Therapy in an HIV-Infected Cohort in Cape Town. PLoS ONE, 2012, 7, e52489.	2.5	13
115	Immunological characterisation of an unmasking TB-IRIS case. South African Medical Journal, 2012, 102, 512.	0.6	12
116	Inflammatory profile of patients with tuberculosis with or without HIV-1 co-infection: a prospective cohort study and immunological network analysis. Lancet Microbe, The, 2021, 2, e375-e385.	7.3	12
117	Modulation of peptide specific T cell responses by non-native flanking regions. Molecular Immunology, 1997, 34, 1237-1246.	2.2	10
118	Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus–1. Clinical Infectious Diseases, 2019, 69, 295-305.	5 . 8	10
119	Tuberculosis Antigen-Specific T-Cell Responses During the First 6 Months of Antiretroviral Treatment. Journal of Infectious Diseases, 2020, 221, 162-167.	4.0	9
120	The immunopathogenesis of tuberculous pericarditis. Microbes and Infection, 2020, 22, 172-181.	1.9	9
121	Tuberculosis infection and disease in South African adolescents with perinatally acquired HIV on antiretroviral therapy: a cohort study. Journal of the International AIDS Society, 2021, 24, e25671.	3.0	9
122	Specificity and Function of Immunogenic Peptides from the 35-Kilodalton Protein of <i>Mycobacterium leprae </i> . Infection and Immunity, 1999, 67, 1501-1504.	2.2	8
123	Immune Responses to Recombinant Proteins of Mycobacterium leprae. Journal of Infectious Diseases, 1999, 179, 1034-1037.	4.0	8
124	QuantiFERON conversion following tuberculin administration is common in HIV infectionÂand relates to baseline response. BMC Infectious Diseases, 2016, 16, 545.	2.9	8
125	Contribution of APCs to mucosal-associated invariant T cell activation in infectious disease and cancer. Innate Immunity, 2018, 24, 192-202.	2.4	8
126	Effect of prednisolone on inflammatory markers in pericardial tuberculosis: A pilot study. IJC Heart and Vasculature, 2018, 18, 104-108.	1.1	8

#	Article	IF	CITATIONS
127	Elevated Matrix Metalloproteinase Concentrations Offer Novel Insight Into Their Role in Pediatric Tuberculous Meningitis. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 82-86.	1.3	6
128	Impairment of IFN-Gamma Response to Synthetic Peptides of Mycobacterium tuberculosis in a 7-Day Whole Blood Assay. PLoS ONE, 2013, 8, e71351.	2.5	5
129	Functional and Activation Profiles of Mucosal-Associated Invariant T Cells in Patients With Tuberculosis and HIV in a High Endemic Setting. Frontiers in Immunology, 2021, 12, 648216.	4.8	5
130	Antiretroviral Treatment-Induced Decrease in Immune Activation Contributes to Reduced Susceptibility to Tuberculosis in HIV-1/Mtb Co-infected Persons. Frontiers in Immunology, 2021, 12, 645446.	4.8	5
131	Brief Report: HIV-1 Infection Impairs CD16 and CD35 Mediated Opsonophagocytosis of Mycobacterium tuberculosis by Human Neutrophils. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 263-267.	2.1	4
132	Kinetics of Mycobacterium tuberculosis-specific IFN- \hat{l}^3 responses and sputum bacillary clearance in HIV-infected adults during treatment of pulmonary tuberculosis. Tuberculosis, 2015, 95, 463-469.	1.9	3
133	The effect of antiretroviral treatment on selected genes in whole blood from HIV-infected adults sensitised by Mycobacterium tuberculosis. PLoS ONE, 2018, 13, e0209516.	2.5	3
134	HIV-Associated Tuberculosis 2012. Clinical and Developmental Immunology, 2012, 2012, 1-2.	3.3	2
135	Human Immunodeficiency Virus-Associated Tuberculosis. Clinical and Developmental Immunology, 2011, 2011, 1-3.	3.3	1
136	Sebum Transforming Growth Factor \hat{I}^21 Induced by Hair Products. Archives of Dermatology, 2012, 148, 764-6.	1.4	1
137	Biomarkers for Identifying Risk of Immune Reconstitution Inflammatory Syndrome. EBioMedicine, 2016, 4, 9-10.	6.1	1
138	Targeting Unconventional T Cells for Vaccination against Tuberculosis. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 401-402.	2.9	1
139	Neutrophil-mediated innate immune resistance to mycobacteria. Journal of Infection, 2008, 56, 301-302.	3.3	0
140	Abstract S03-02: Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study., 2021,,.		0
141	Immune Network Analysis Reveals Interleukin-17A Related Responses As Key Contributors to HIV-1 Associated Tuberculosis. SSRN Electronic Journal, 0, , .	0.4	0